JP2024016207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016207A5 JP2024016207A5 JP2023191314A JP2023191314A JP2024016207A5 JP 2024016207 A5 JP2024016207 A5 JP 2024016207A5 JP 2023191314 A JP2023191314 A JP 2023191314A JP 2023191314 A JP2023191314 A JP 2023191314A JP 2024016207 A5 JP2024016207 A5 JP 2024016207A5
- Authority
- JP
- Japan
- Prior art keywords
- fab
- liquid suspension
- hvegf
- eye
- raav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006194 liquid suspension Substances 0.000 claims 31
- 241000702421 Dependoparvovirus Species 0.000 claims 14
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 claims 10
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims 10
- 230000001105 regulatory effect Effects 0.000 claims 7
- 108091026890 Coding region Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 210000000234 capsid Anatomy 0.000 claims 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 229960003876 ranibizumab Drugs 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 102000007469 Actins Human genes 0.000 claims 2
- 108010085238 Actins Proteins 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 2
- 102100037935 Polyubiquitin-C Human genes 0.000 claims 2
- 108010056354 Ubiquitin C Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010025421 Macule Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 208000002352 blister Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632775P | 2018-02-20 | 2018-02-20 | |
| US62/632,775 | 2018-02-20 | ||
| US201862663532P | 2018-04-27 | 2018-04-27 | |
| US62/663,532 | 2018-04-27 | ||
| PCT/US2019/018640 WO2019164854A1 (en) | 2018-02-20 | 2019-02-19 | Compositions for treatment of wet age-related macular degeneration |
| JP2020543914A JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Division JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024016207A JP2024016207A (ja) | 2024-02-06 |
| JP2024016207A5 true JP2024016207A5 (enExample) | 2024-08-13 |
Family
ID=67688300
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Pending JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2023191314A Pending JP2024016207A (ja) | 2018-02-20 | 2023-11-09 | 滲出型加齢性黄斑変性の治療のための組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Pending JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210093734A1 (enExample) |
| EP (1) | EP3755804A4 (enExample) |
| JP (2) | JP2021516671A (enExample) |
| KR (1) | KR20210022524A (enExample) |
| AU (2) | AU2019223963A1 (enExample) |
| CA (1) | CA3090293A1 (enExample) |
| IL (1) | IL276777B1 (enExample) |
| MA (1) | MA51916A (enExample) |
| SG (1) | SG11202007252VA (enExample) |
| WO (1) | WO2019164854A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3568774A1 (en) * | 2017-01-12 | 2019-11-20 | Telefonaktiebolaget LM Ericsson (PUBL) | Anomaly detection of media event sequences |
| KR20200060456A (ko) * | 2017-09-27 | 2020-05-29 | 리젠엑스바이오 인크. | 완전-인간 번역후 변형된 항-VEGF Fab를 이용한 안구 질환의 치료 |
| JP2021506861A (ja) | 2017-12-19 | 2021-02-22 | アコーオス インコーポレイテッド | 内耳への治療用抗体のａａｖ媒介送達 |
| US11360969B2 (en) * | 2019-03-20 | 2022-06-14 | Promethium, Inc. | Natural language based processing of data stored across heterogeneous data sources |
| WO2021046245A1 (en) * | 2019-09-04 | 2021-03-11 | University Of Massachusetts | Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof |
| US20230139443A1 (en) * | 2020-02-28 | 2023-05-04 | The Trustees Of The University Of Pennsylvania | Treating autosomal dominant bestrophinopathies and methods for evaluating same |
| US20230152336A1 (en) * | 2020-04-24 | 2023-05-18 | Siemens Healthcare Diagnostics Inc. | Calibration and quality control reagents for use with immunoassays for antibodies and methods of production and use thereof |
| WO2021255590A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof |
| WO2021255589A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof |
| AU2021362770A1 (en) | 2020-10-16 | 2022-12-08 | Gyroscope Therapeutics Limited | Nucleic acid encoding an anti-VEGF entity and a negative complement regulator and uses thereof for the treatment of age-related macular degeneration |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| US20240335562A1 (en) * | 2021-08-04 | 2024-10-10 | Alpine Biotherapeutics Corporation | Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders |
| CN114181972A (zh) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体 |
| KR102789747B1 (ko) * | 2021-12-29 | 2025-04-03 | 한국과학기술원 | Prox1 단백질에 중화 활성을 갖는 결합 분자 |
| AU2023215253A1 (en) * | 2022-02-02 | 2024-09-19 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| WO2024238859A1 (en) * | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized c5 inhibitor agents and administration thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120622A1 (es) * | 2009-06-17 | 2012-05-26 | Abbott Biotherapeutics Corp | Anticuerpos anti-vegf y sus usos |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| MA44873A (fr) * | 2016-04-15 | 2019-03-13 | Univ Pennsylvania | Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative |
| AU2017250797A1 (en) * | 2016-04-15 | 2018-10-25 | Regenxbio Inc. | Treatment of ocular diseases with fully-human post-translationally modified anti-VEGF fab |
-
2019
- 2019-02-18 US US16/971,215 patent/US20210093734A1/en active Pending
- 2019-02-19 EP EP19757101.1A patent/EP3755804A4/en active Pending
- 2019-02-19 AU AU2019223963A patent/AU2019223963A1/en not_active Abandoned
- 2019-02-19 SG SG11202007252VA patent/SG11202007252VA/en unknown
- 2019-02-19 JP JP2020543914A patent/JP2021516671A/ja active Pending
- 2019-02-19 KR KR1020207026455A patent/KR20210022524A/ko active Pending
- 2019-02-19 WO PCT/US2019/018640 patent/WO2019164854A1/en not_active Ceased
- 2019-02-19 CA CA3090293A patent/CA3090293A1/en active Pending
- 2019-02-19 MA MA051916A patent/MA51916A/fr unknown
-
2020
- 2020-08-18 IL IL276777A patent/IL276777B1/en unknown
-
2023
- 2023-11-09 JP JP2023191314A patent/JP2024016207A/ja active Pending
-
2025
- 2025-06-25 AU AU2025204780A patent/AU2025204780A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016207A5 (enExample) | ||
| JP2022153418A5 (enExample) | ||
| KR102616820B1 (ko) | 향상된 유전자 발현을 위한 조성물 및 방법 | |
| JP2021503914A5 (enExample) | ||
| JP2025000642A5 (enExample) | ||
| JP2019518427A5 (enExample) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| JP2020510424A5 (enExample) | ||
| JP7410522B2 (ja) | 抗ｆａｍ１９ａ５抗体のアデノ関連ウイルス（ａａｖ）伝達 | |
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| JP2011512417A (ja) | 血管形成の阻害 | |
| EP4549459A1 (en) | Aav drug for treating angiogenesis-related fundus diseases | |
| CA2995849A1 (en) | Chimeric aav-anti-vegf for treating cancer in canines | |
| JPWO2019164854A5 (enExample) | ||
| US20200297869A1 (en) | Sequential intravitreal administration of aav gene therapy to contralateral eyes | |
| US20150182638A1 (en) | Virus-mediated delivery of bevacizumab for therapeutic applications | |
| KR20240150793A (ko) | Vegf 결합 분자 및 이의 의약적 용도 | |
| KR20240116840A (ko) | 변형된 aav 캡시드 단백질 및 이의 용도 | |
| CN118853712A (zh) | 编码抗vegf蛋白的核酸、多核苷酸表达盒及重组腺相关病毒 | |
| CN116983434A (zh) | 用于基因治疗的核酸构建体及其用途 | |
| US20240279324A1 (en) | Multispecific antagonists | |
| JPWO2021041373A5 (enExample) | ||
| JPWO2020180951A5 (enExample) | ||
| KR20240107201A (ko) | 항원-결합 분자 및 이의 용도 | |
| CN117070541A (zh) | 编码抗vegf蛋白的多核苷酸表达盒、质粒及重组腺相关病毒 |